期刊文献+

125I粒子植入治疗非小细胞肺癌的剂量学优化研究 被引量:16

Dosimetric optimization of 125I seed implantation and improvement of the therapeutic outcome for treating non-small cell lung cancer
原文传递
导出
摘要 目的 通过实施放射剂量学优化等质量保证和质量控制措施,提高125I粒子植入治疗NSCLC的增益比.方法 经临床、支气管镜、影像学诊断及病理检查证实的NSCLC患者246例,其中男158例,女88例,平均年龄61.7岁;分别采用CT、18F-FDG符合线路显像和纤维支气管镜(FFB)进行靶区定位;应用TPS制定方案并优化,以剂量-体积直方图(DVH)等评估TPS;影像引导125I粒子植入,并进行实时位置验证、植入后剂量学验证、疗效判定和随访.结果 CT引导植入组的137例中129例植入粒子数与TPS计划粒子数及分布一致,符合率达94.16% (129/137);早期和晚期放射反应发生率分别为12.41%(17/137)%和2.19%(3/137);匹配周缘剂量(MPD)最高达92.1 Gy,PTV外危及器官(心、肺及脊髓)的平均照射剂量明显低于正常组织耐受剂量,局部控制总有效率为91.97%(126/137),1年和2年生存率分别为91.24%(125/137)和50.36% (69/137);18F-FDG符合线路显像引导植入组和FFB引导植入组的局部控制总有效率分别为91.43%(32/35)和77.27%(51/66),1年生存率分别为88.57%(31/35)和80.30% (53/66);未发现放射性肺炎或肺纤维化.结论 适当采用生物靶区定位和规范实施质量保证和质量控制,是提高影像引导下125I粒子植入治疗增益比的保证,能够为无法耐受手术、根治放疗或全身化疗的NSCLC患者提供一种有效且低损的疗法. Objective To implement a dose optimization programme and improve the therapeutic gain ratio of 125I seed implantation in patients with stage Ⅲb to Ⅳ NSCLC.Methods A total of 246 NSCLC patients (158 males,88 females,mean age 61.7 years) were enrolled into this study.The target was located by CT,18F-FDG coincidence SPECT/CT or flexible fiberoptic bronchoscopy (FFB).The treatment plan was generated and optimized by TPS,which was evaluated according to the dose volume histograms (DVH).125I seeds were implanted and intraoperative position was validated in real time under guidance of imaging.Dosimetry was validated,and therapeutic efficiency was evaluated.The 1-and 2-year survival rates were calculated.Results The number and distribution of the implanted seeds were accorded with those planned by TPS in 129 of 137 cases (94.16%) in CT guided implantation group.The matched peripheral dose (MPD) was 92.1 Gy.The average dose of organs at risk such as heart,lung and spinal cord was significantly lower than the normal tissue tolerance dose.The early and late radioactive response rates were 12.41%(17/137) and 2.19%(3/137) respectively,and 91.97%(126/137) was under local control.The 1-and 2-year survival rates was 91.24 %(125/137) and 50.36 %(69/137) respectively.In SPECT/CT and FFB guided implantation groups,88.57%(31/35) and 77.27%(51/66) were under local control respectively,and 1-year survival rates were 91.43% (32/35) and 80.30% (53/66) respectively.Radiation pneumonitis and pulmonary fibrosis were not detected in all 3 groups.Conclusion Standard application of quality assurance and quality control is the guarantee of the improvement of therapeutic gain ratio of seed implantation guided by image.
出处 《中华核医学与分子影像杂志》 北大核心 2015年第1期36-40,共5页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 天津市卫生局科技基金(2010KZl00) 天津医科大学第二临床学院科研基金(Y200404)
关键词 非小细胞肺 近距离放射疗法 碘放射性同位素 Carcinoma,non-small-cell lung Brachytherapy Iodine radioisotopes
作者简介 通信作者:王平,Email:wangping@tjmuch.com
  • 相关文献

参考文献12

  • 1邓小武.放射治疗计划设计//徐向英,曲雅勤.肿瘤放射治疗学[M].2版.北京:人民卫生出版社.2010:45—51.
  • 2李小东,李亚明.重视放射性粒子植入治疗的规范化[J].中华核医学与分子影像杂志,2013,33(4):241-242. 被引量:7
  • 3宇传华.生存率的估计与生存曲线//孙振球.医学统计学[M].3版.北京:人民卫生出版社,2010:306-309.
  • 4曾自力,刘兵.三维适形放疗计划轮照对肺癌剂量分布影响的研究[J].中国医学物理学杂志,2011,28(2):2471-2474. 被引量:6
  • 5廖安燕,王俊杰.持续低剂量率照射治疗前列腺癌的生物学效应[J].国外医学(放射医学核医学分册),2005,29(4):190-192. 被引量:3
  • 6Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy [J]. Int J Radiat Oncol Biol Phys, 2002, 54(2) : 462-470.
  • 7傅小龙.原发性非小细胞肺癌//李少林,吴永忠.肿瘤放射治疗学[M].北京:科学出版社,2013:293-316.
  • 8Sanzs CD, Rostelato MECM, Zeituni CA, et al. Analysis of the necessary radioprotection procedures in manufacture of iodine-125 sources used in brachytheray : a preliminary study [ J ]. Prog Nucl Energy, 2011, 53(1): 66-72.
  • 9Colonias A, Betler J, Trombetta M, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sub- lobar resection and intraoperative iodine-125 brachytherapy[ J ]. Int J Radiat Oncol Biol Phys, 2011, 79(1) : 105-109.
  • 10Sylvester JE, Grimm PD, Wang J, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following 15I prostate brachytherapy in clinically localized prostate cancer: Seattle experience [ J ]. Int J Radiat Oncol Biol Phys, 2011, 81(2) : 376-381.

二级参考文献16

  • 1肖泽芬,章众,张红志,戴建荣,梁军,韩伟.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277. 被引量:174
  • 2Pasteau 0,Deg rais P. The radium treatment of cancer of the pros-tate. Arch Roentgen Ray, 1914,28: 396-410.
  • 3Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percu-taneous implantation of 1251 sources with CT treatment planning.Radiology, 1987, 164: 735-740.
  • 4胡洪涛.放射物理基础//徐向英,曲雅勤.肿瘤放射治疗学.2版.北京:人民卫生出版社,2013: 14.
  • 5Sylvester JE, Grimm PD, Wong J, et al. Fifteen-year biochemicalrelapse-free survival, cause-specific survival, and overall survivalfollowing 1251 prostate brachytherapy in clinically localized prostatecancer: Seattle experience. Int J Radiat Oncol Biol Phys, 2011,81: 376-381.
  • 6Colonias A,Betler J,Trombetta M, et al. Mature follow-up forhigh-risk stage I non-small-cell lung carcinoma treated with sub-lobar resection and intraoperative 1251 brachytherapy. Int J RadiatOncol Biol Phys, 2011, 79: 105-109.
  • 7Wang ZM,Liu Y,Liu FJ,et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreaticcancer. Eur Radiol,2010, 20: 1786-1791.
  • 8Yamamoto Y, Nishiyama Y, Monden T, et al. Clinical usefulnessof fusion of 1311 SPECT and CT images in patients with differentia-ted thyroid carcinoma. J Nucl Med, 2003,44: 1905-1910.
  • 9Nag S, Ellis RJ, Merrick GS, et al. American Brachytherapy Societyrecommendations for reporting morbidity after prostate brachytherapy.Int J Radiat Oncol Biol Phys, 2002,54: 462-470.
  • 10陈东福等著,殷蔚伯,谷铣之.肿瘤放射治疗学[M]中国协和医科大学出版社,2002.

共引文献11

同被引文献109

引证文献16

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部